Board of Directors

Tim Robinson, Chief Financial Officer

Timothy C. Robinson
Andelyn Biosciences Chairman of the Board
Nationwide Children's Hospital CEO

Tim Robinson is the chief executive officer of Nationwide Children’s Hospital. Mr. Robinson first joined Nationwide Children’s in 1995, and his innovative approach to navigating complex economic, regulatory and business challenges has helped the hospital transform from an important regional children’s health care system into a preeminent  academic medical center. Nationwide Children’s now appears annually on the U.S. News & World Report list of top ten children’s hospitals, and it is one of the National Institutes of Health’s top funded freestanding pediatric research facilities.

In his 25 years with Nationwide Children’s, Mr. Robinson has held the titles of assistant treasurer, senior vice president, executive vice president and chief financial and administrative officer. He is credited with building the hospital’s investment portfolio from $100 million to almost $3 billion, and leading the hospital to earn an Aa2 bond rating consistently since 2001. 
Mr. Robinson was a key leader as Nationwide Children’s completed the largest pediatric campus expansion in United States history in 2012, including the opening of a new 12-story main hospital tower and the doubling of campus space devoted to research. He is continuing to guide a $760 million, second-phase expansion, including the country’s largest pediatric behavioral health clinical and research facility, which opened in March, 2020.

During his tenure as chief financial officer, Mr. Robinson led groundbreaking efforts in population health. Partners For Kids, now one of the country’s oldest and largest pediatric accountable care organizations, has grown from responsibility for 13,000 children to approximately 419,000 children under Mr. Robinson’s leadership. He has also been a driving force behind the Healthy Neighborhoods Healthy Families initiative, which has become a national model for health systems to improve housing, educational opportunities and public safety in their communities.

More recently, Mr. Robinson has championed research and related technology commercialization efforts. The hospital’s scientists had 10 patents issued in 2015; in 2018, there were more than 40. A total of 14 companies have now been created based on Nationwide Children’s medical and scientific discoveries. In January 2020, the hospital’s internationally-recognized expertise in gene therapy led it to launch Andelyn Biosciences, an affiliate company that will manufacture gene therapy products for the biotechnology and pharmaceutical industry.

Mr. Robinson has served as the treasurer of the Nationwide Children’s Hospital Board and a number of hospital subsidiary boards, including its physician practice groups and homecare company. He currently serves on the board of the Ohio Children’s Hospital Association, and the Children’s Hospital Association’s public policy committee. He is also on the board of Rev1 Ventures, which partners with The Abigail Wexner Research Institute at Nationwide Children’s to accelerate the formation and growth of life science companies in central Ohio.

Mr. Robinson earned his bachelor’s of science degree from Indiana University, where he double majored in Psychology and Business Administration, and he is a Certified Cash Manager.  He and his wife, Jane, reside in Bexley, Ohio. They are parents to Lauren, Andrea and Jordan.

Michael Triplett

Michael Triplett, PhD
Founder, President & CEO, Armatus Bio, Inc.
Founder and Co-Chairman, Clarametyx Biosciences, Inc.

Dr. Michael Triplett is co-founder, President, and CEO of Armatus Bio, Inc., a multi-asset gene and cell therapy company based in Columbus, Ohio developing next generation therapies for neuromuscular diseases, neurodegenerative diseases, and cancer. Dr. Triplett is co-founder and co-Chairman of Clarametyx Biosciences, Inc., an early-stage infectious disease company pursuing paradigm shifting therapeutics and vaccines for the treatment and prevention of bacterial biofilm mediated diseases, after serving as founding President and CEO. Dr. Triplett co-founded and served as President and CEO of Myonexus Therapeutics, a clinical stage gene therapy company developing first-ever treatments for limb-girdle muscular dystrophies acquired by Sarepta Therapeutics for >$225 million in April 2019.

Dr. Triplett began his career at Procter & Gamble as a Product Development Engineer prior to attending graduate school. After completing his graduate work in nanoparticle engineering as a U.S. Department of Defense National Defense Science and Engineering Graduate Fellow, he joined Battelle where he held roles of progressing responsibility, spanning business development, innovation, new venture development, corporate ventures, and strategy in the Health & Life Sciences Global Business. Prior to co-founding Myonexus Therapeutics, Dr. Triplett served as Chief Executive Officer of N8 Medical, a clinical stage combination device company with Breakthrough designation for its lead antimicrobial endotracheal tube product.

Excelling at the interfaces of business and biotech innovation, Dr. Triplett is passionate about translating world-class science and technology into transformative businesses, products, and capabilities that enhance human health, American competitiveness, and economic opportunity. Dr. Triplett focuses on life sciences technology ventures, innovation, technology-based economic development, and science, technology, engineering and math (STEM) education.

Dr. Triplett is currently leading an InnovateOhio Gene and Cell Therapy Working Group for Ohio Lieutenant Governor Jon Husted with the mission of proposing gene and cell therapy economic development strategies to grow the industry within the State of Ohio.

Dr. Triplett received his B.S. in Chemical Engineering (summa cum laude) and Ph.D. in Chemical Engineering from The Ohio State University as a United States Department of Defense National Defense Science and Engineering Graduate Fellow and University Fellow.

Alex Fischer

Alex R. Fischer
President and CEO, The Columbus Partnership

Alex Fischer is the President and CEO of the Columbus Partnership, a civic organization of Columbus, Ohio’s, top business leaders formed in 2002 to improve the economic and cultural base of Central Ohio. The Partnership is helping to lead the One Columbus economic development effort, which is a collaboration of regional economic development organizations, and is involved with education reform efforts with Columbus City Schools. The Partnership’s members include 15 Fortune 1000 CEOs, as well as the leaders of the nation’s largest university and world’s largest research and development organization.

The Columbus Partnership played a key role in winning the U.S. Department of Transportation’s “Smart City Challenge” to bring $50 million of grant funding to the city and receiving official designation as the “Smart City” of North America. Fischer serves as Co-Chairman of Smart Columbus and leads the private-sector efforts to make Columbus a pioneer in smart mobility.

Fischer has been active on numerous for-profit boards and community organizations including serving as the past Chairman of Veloycs, OmniViz and the SunTrust Bank of East Tennessee Board of Directors. He currently serves as Chairman of Nationwide Children’s Hospital, which is ranked by U.S. News & World Report as one of the Best Children’s Hospitals and is one of the nation’s largest not-for-profit freestanding pediatric healthcare networks, as well as home to one of the top 10 National Institutes of Health-funded freestanding pediatric research facilities. Fischer is a Trustee of The Ohio State University and on the boards of Advanced Drainage Systems, One Columbus, Nationwide Children’s Championship, The Ohio State Innovation Foundation, and the Advisory Board for White Oak Partners, LLC.

Prior to joining the Columbus Partnership, Fischer was Senior Vice President for Business and Economic Development for Battelle headquartered in Columbus, Ohio, and served on the company’s Executive Committee and as a corporate officer. His responsibilities included commercialization of Battelle’s technologies including six national laboratories managed or co-managed by Battelle. In this role, he served as one of the primary interfaces with Battelle’s venture capital investments. Fischer also oversaw the office of Public Affairs and Government Relations, Battelle’s Economic Development programs, as well as Business Development activities. In this post, he spearheaded Battelle’s successful bid of the National Renewable Energy Laboratory as well as the UK’s new National Nuclear Laboratory.

Bob Kidder

C. Robert Kidder
Nationwide Children's Hospital Board of Trustees

Mr. Kidder currently serves on the boards of Advanced Drainage Systems, Inc.; Microvi Biotech; Wildcat Discovery; Cohn Robbins Holding Corp.; and Andelyn Biosciences.  In addition, he serves on the Boards of Trustees of Nationwide Children’s Hospital and the Wexner Center Foundation.  Mr. Kidder is a former board member of Morgan Stanley, Merck, and Chrysler.  He co-founded 3Stone Advisors LLC in 2006, a private equity business focused on water investment.  He was Chairman and Chief Executive Officer of Borden, Inc. from January 1995 through 2004 and Duracell for the prior ten years. Both Borden and Duracell were KKR-led leveraged buyouts.  Mr. Kidder earned a B.S. in industrial engineering from the University of Michigan and a graduate degree in industrial economics from Iowa State University.

Andelyn Biosciences Board of Directors

Joseph Repp
President, Pall Life Sciences

Joe joined Pall in July 2020 after 11 years with Beckman Coulter, where he most recently served as the President for Beckman Coulter Microbiology. Under Joe’s leadership, Beckman Coulter Microbiology consistently increased core growth and accelerated new product introductions. Prior assignments with BEC/Danaher include VP of Global Operations and Site Leader for Chaska and Lumigen Business Unit, VP of Global Operations & Business Development for BEC MDX, and VP/GM of BEC Genomics BU. Prior to joining Beckman, Joe worked with Becton Dickinson for more than 14 years, where he served in various commercial, operational and general management roles of increasing responsibility. Joe earned his Bachelor of Science degree from Binghamton University and a Master of Business Administration degree from Suffolk University in Boston, MA.

Andelyn Biosciences Board of Directors

Edward Hoare
VP & GM, Pall Biotech

Edward Hoare leads the Biotech organization for Pall (a Danaher company).

Edward joined Pall in 1986 as a sales engineer in the UK. Through the years, he held key roles of increasing responsibility including President of Biopharmaceuticals Americas, Senior Vice President of Global Commercial Operations, President of Life Sciences Europe and President, Pall Americas. Throughout his tenure at Pall, Edward worked all over the world in most Pall markets, and lived for many years in the United States, United Kingdom and Switzerland.

In his current role, Ed leads the Biotech business team delivering quality products and services, improving customer experience and business growth. His background as a chemical engineer compliments his extensive knowledge of Pall’s technologies, markets and operations, as well as his deep management experience. 

Edward has a Bachelor of Science degree in Chemical Engineering from the Cork Institute of Technology and an MBA from Columbia Business School and London Business School.

Andelyn Biosciences Board of Directors

Jeff Szekeres
Vice President, Corporate Development, Danaher Corporation 

Jeff Szekeres is currently Vice President, Corporate Development for Danaher Corporation (DHR) where he is responsible for leading corporate development efforts (including acquisition, divestitures, minority investments and strategic partnerships) for operating companies in Danaher’s Life Sciences and Diagnostics segment (~$13B 2020 revenues). Notable deals since joining Danaher include ~$45B in transactions including Cytiva, Pall, Cepheid, Integrated DNA Technologies, Phenomenex, Devicor Medical, Hemocue, Siemens Microbiology, Xitogen Technologies, Andelyn Biosciences, Singel Use Support, Labcyte, VanRx Pharmasystems, IDBS, m2p Labs, Intabio, Kreatech, Bioptigen, Swift Biosciences and Normand.  

Prior to joining Danaher in September 2012, Jeff was Vice President, Head of Mergers & Acquisitions at Life Technologies (LIFE), a $3.8B global provider of life science and diagnostic products and services to research, medical, and applied markets. While at LIFE, Jeff managed a four person corporate development team and guided 30+ transactions totaling more than $9B, including acquisitions, divestitures, joint ventures, equity investments and intellectual property partnerships. 

Before joining Life Technologies in August 2005, Jeff received an MBA in Finance with Honors from the Wharton School and a Masters of Biotechnology from the University of Pennsylvania School of Engineering and Applied Sciences. 

Prior to his graduate studies, Jeff held management consulting positions at the Monitor Group and Roll International in Los Angeles, CA. During his tenure in consulting, Jeff conducted engagements in industries including biotechnology, entertainment, agriculture, consumer products and Internet. 

Jeff holds a Bachelor’s Degree in human biology and genetics from Stanford University. Jeff currently holds three Director positions on the Board of Directors for companies in the areas of bioprocess and genomics. Jeff previously held a Director position on the Board of Directors of OligoCo, a life science technology start-up based in Bothell, WA from 2009 to 2012. 

Jeff lives with his wife and three children ages 7 to 12 years old in Solana Beach, CA and enjoys hiking, mountain biking and skiing.